Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
AuthorSaharia, Kapil K
Husson, Jennifer S
Niederhaus, Silke V
Avila, Stephanie V
Yoo, Youngchae J
Hardy, Nancy M
Xie, Wen Y
Vander Mause, Erica
Mannuel, Heather D
Rapoport, Aaron P
JournalClinical & Translational Immunology
MetadataShow full item record
AbstractFollowing the initial vaccination series, 60.3% of SOTR showed no measurable neutralisation and only 18.9% demonstrated neutralising activity of > 90%. More intensive immunosuppression, antimetabolites in particular, negatively impacted antiviral immunity. While absolute IgG levels were lower in SOTR than controls, antibody titres against microbial recall antigens were higher. By contrast, SOTR showed reduced vaccine-induced IgG/IgA antibody titres against SARS-CoV-2 and its delta variants and fewer linear B-cell epitopes, indicating reduced B-cell diversity. Importantly, a third vaccine dose led to an increase in anti-SARS-CoV-2 antibody titres and neutralising activity across alpha, beta and delta variants and to the induction of anti-SARS-CoV-2 CD4+ T cells in a subgroup of patients analysed. By contrast, we observed significantly lower antibody titres after the third dose with the omicron variant compared to the ancestral SARS-CoV-2 and the improvement in neutralising activity was much less pronounced than for all the other variants.
Rights/Terms© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18773
- Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
- Authors: Aleem A, Akbar Samad AB, Slenker AK
- Issue date: 2022 Jan
- Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
- Authors: Benning L, Morath C, Bartenschlager M, Kim H, Reineke M, Beimler J, Buylaert M, Nusshag C, Kälble F, Reichel P, Töllner M, Schaier M, Klein K, Benes V, Rausch T, Rieger S, Stich M, Tönshoff B, Weidner N, Schnitzler P, Zeier M, Süsal C, Hien Tran T, Bartenschlager R, Speer C
- Issue date: 2022 Jul
- Humoral immune response after different SARS-CoV-2 vaccination regimens.
- Authors: Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A
- Issue date: 2022 Jan 21
- Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
- Authors: Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Dyrdak R, Martin DP, Reddy ST, Dillner J, Karlsson Hedestam GB, Albert J, Murrell B
- Issue date: 2022 Jun
- Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
- Authors: Lavezzo E, Pacenti M, Manuto L, Boldrin C, Cattai M, Grazioli M, Bianca F, Sartori M, Caldart F, Castelli G, Nicoletti M, Nieddu E, Salvadoretti E, Labella B, Fava L, Vanuzzo MC, Lisi V, Antonello M, Grimaldi CI, Zulian C, Del Vecchio C, Plebani M, Padoan A, Cirillo DM, Brazzale AR, Tonon G, Toppo S, Dorigatti I, Crisanti A
- Issue date: 2022 Jun 10